Table 3 Percentage of patients that developed adverse effects to TKI
Unwanted effect | Afatinib (n = 40) | Erlotinib (n = 26) | Gefitinib (n = 33) | |||
|---|---|---|---|---|---|---|
Any Grade | Grade 3–4 | Any Grade | Grade 3–4 | Any Grade | Grade 3–4 | |
Any unwanted effect | 36 (90%) | 3 (7.5%) | 26 (100%) | 4 (15.4%) | 26 (78.8%) | 1 (3%) |
• Rash | 23 (57.5%) | 1 (2.5%) | 13 (50%) | 1 (3.8%) | 13 (39.4%) | 0 (0.0%) |
• Diarrhea | 14 (35%) | 2 (5%) | 13 (50%) | 2 (7.7%) | 18 (54.5%) | 0 (0.0%) |
• Xerosis | 16 (40%) | 0 (0.0%) | 9 (34.6%) | 0 (0.0%) | 12 (36.4%) | 0 (0.0%) |
• Paronychia | 11 (27.5%) | 0 (0.0%) | 4 (15.4%) | 0 (0.0%) | 4 (12.1%) | 0 (0.0%) |
• Nausea | 3 (7.5%) | 0 (0.0%) | 7 (26.9%) | 0 (0.0%) | 7 (21.2%) | 0 (0.0%) |
• Acne | 6 (15%) | 0 (0.0%) | 6 (23.1%) | 0 (0.0%) | 1 (3%) | 0 (0.0%) |
• Fatigue | 5 (12.5%) | 0 (0.0%) | 6 (23.1%) | 0 (0.0%) | 2 (6.1%) | 0 (0.0%) |
• Stomatitis | 6 (15%) | 0 (0.0%) | 5 (19.2%) | 0 (0.0%) | 5 (15.2%) | 0 (0.0%) |
• Constipation | 2 (5%) | 0 (0.0%) | 4 (15.4%) | 0 (0.0%) | 3 (9.1%) | 0 (0.0%) |
• Vomit | 2 (5%) | 0 (0.0%) | 3 (11.5%) | 0 (0.0%) | 1 (3%) | 0 (0.0%) |
• Alopecia | 1 (2.5%) | 0 (0.0%) | 0 (0%) | 0 (0.0%) | 3 (9.1%) | 1 (3%) |
• Neuropathy | 2 (5%) | 0 (0.0%) | 0 (0%) | 0 (0.0%) | 3 (9.1%) | 0 (0.0%) |
• Anorexia | 3 (7.5%) | 0 (0.0%) | 0 (0%) | 0 (0.0%) | 1 (3%) | 0 (0.0%) |
• Liver toxicity | 0 (0%) | 0 (0.0%) | 1 (3.8%) | 0 (0.0%) | 0 (0%) | 0 (0.0%) |
• Anemia | 0 (0%) | 0 (0.0%) | 0 (0%) | 0 (0.0%) | 1 (3%) | 0 (0.0%) |
• Arthralgia | 1 (2.5%) | 0 (0.0%) | 0 (0%) | 0 (0.0%) | 1 (3%) | 0 (0.0%) |